early cancer detection News
-
IONIQ Sciences announces IP acquisition and License buyou
ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has acquired from OT Acceptance, LLC (“OT Acceptance”) certain intellectual property formerly licensed to the Company by OT Acceptance. With this acquisition, the Company now owns (rather than licenses) all of the intellectual property used by it with respect to early ...
-
Rocío Arroyo, CEO of Amadix, has been chosen as one of the protagonists of change in 2022 in the list made by Forbes.
This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world. Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix. Read the ...
By Amadix
-
IONIQ Sciences submits De Novo application to FDA for IONIQ ProLung Test
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has filed a De Novo application with the U.S. Food and Drug Administration (the “FDA”) for its IONIQ ProLung Test™ used for lung cancer. Mr. Jared Bauer, IONIQ Sciences CEO, stated, “Today we submitted our De Novo application for marketing clearance to the FDA for our IONIQ ...
-
GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot
“We applaud President Biden for reigniting the Cancer Moonshot and highlighting the critical role of early detection in achieving the ambitious, but attainable, goal of reducing the cancer death rate by at least 50 percent in the next 25 years. Improving quality of life for patients and survivors, while addressing inequities in access to cancer screening, diagnostics and treatment is a ...
By Grail, Inc.
-
IONIQ Sciences hires Edison Group as Investor Relations Advisor
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has hired Edison Group, a leading investor relations and research firm, to assist with its investor relations program. Edison Group, established in 2003, is an investor relations, investor research, and consulting firm. With broad sector knowledge, analyst resources and deep capital markets expertise, ...
-
IONIQ Sciences is awarded “Best of Salt Lake City – Cancer Testing 2021”
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to announce it has been awarded “Best of Salt Lake City – Cancer Testing 2021.” We are humbled to have our mission to modernize early-stage cancer detection continue to be recognized nationally and locally. Through our novel application of bioimpedance technology, we believe that we’re ...
-
Circulating atypical cells detected in blood of lung cancer patients
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
By X-Zell Inc.
-
IONIQ Presents Lung Cancer Trial Results at ATS 2022
IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis. Furthermore, the ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Biomark to Present New Cancer Screening Data using the Ldtd-Ms/Ms Technique at The Annual Asms Conference on Mass Spectrometry
BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 – 9, 2022 ...
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. Based in Orange, ...
By Grail, Inc.
-
Calviri Named Most Fundable Company by Pepperdine Graziadio Business School
Calviri, a biotechnology company developing unique products against cancer, is pleased to announce that it was awarded one of three Platinum awards in the Pepperdine Graziadio Business School’s third annual Most Fundable Companies® List. Calviri competed against more than 4,500 early-stage startups from all 50 US states for this top designation. A total of 20 companies, all with less ...
By Calviri
-
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome ...
-
Cleveland Diagnostics Chief Medical Officer, Mark Stovsky, MD, Participates in Panel Discussion on Early Cancer Detection During Cleveland Clinic`s 2019 Medical Innovation Summit
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic. The Medical Innovation Summit, which is celebrating its 17th year, is covering a wide ...
-
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
-
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
By Grail, Inc.
-
Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance ...
By Grail, Inc.
-
Transpara breast AI reduces false positives and radiologists` workload in largest Danish screening programme
The team running the country's largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous contribution of this technology to breast cancer detection: not only to reduce the number of false positives but also to reduce radiologists' workload by over 60%. In Copenhagen, the biannual breast screening programme for women aged from 50 to 69, has been ...
-
GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early ...
By Grail, Inc.
-
Study published in BJC shows strong performance of Tethis’ liquid biopsy test in early stage breast cancer
Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® ...
By Tethis S.p.A
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you